Crestline Management LP lifted its holdings in Reata Pharmaceuticals Inc (NASDAQ:RETA) by 14.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 68,906 shares of the company’s stock after buying an additional 8,442 shares during the quarter. Crestline Management LP owned approximately 0.26% of Reata Pharmaceuticals worth $1,951,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of RETA. Wells Fargo & Company MN lifted its position in shares of Reata Pharmaceuticals by 37.4% in the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock worth $176,000 after buying an additional 1,521 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Reata Pharmaceuticals by 39.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,041 shares of the company’s stock worth $729,000 after buying an additional 6,541 shares during the last quarter. Nationwide Fund Advisors lifted its position in shares of Reata Pharmaceuticals by 38.1% in the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock worth $138,000 after buying an additional 1,206 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Reata Pharmaceuticals by 49.8% in the 2nd quarter. New York State Common Retirement Fund now owns 10,526 shares of the company’s stock worth $333,000 after buying an additional 3,499 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Reata Pharmaceuticals by 39.3% in the 2nd quarter. Northern Trust Corp now owns 98,046 shares of the company’s stock worth $3,102,000 after buying an additional 27,669 shares during the last quarter. Institutional investors own 49.26% of the company’s stock.
A number of research analysts have recently issued reports on RETA shares. Zacks Investment Research downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. BidaskClub upgraded shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research report on Thursday, December 14th. Three analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $54.71.
RETA stock traded up $0.33 during mid-day trading on Wednesday, hitting $22.93. 26,886 shares of the company were exchanged, compared to its average volume of 196,636. The company has a debt-to-equity ratio of -0.13, a quick ratio of 2.80 and a current ratio of 2.80. Reata Pharmaceuticals Inc has a 1-year low of $19.48 and a 1-year high of $40.88. The firm has a market cap of $595.00, a PE ratio of -11.41 and a beta of -0.48.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Friday, March 2nd. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.08). The company had revenue of $9.96 million for the quarter, compared to analyst estimates of $11.18 million. analysts expect that Reata Pharmaceuticals Inc will post -2.54 earnings per share for the current fiscal year.
In related news, Director R Kent Mcgaughy, Jr. bought 17,000 shares of the stock in a transaction on Friday, December 29th. The shares were purchased at an average price of $28.47 per share, with a total value of $483,990.00. Following the purchase, the director now owns 113 shares in the company, valued at $3,217.11. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James W. Traweek, Jr. bought 27,200 shares of the stock in a transaction on Thursday, December 28th. The shares were bought at an average cost of $25.93 per share, for a total transaction of $705,296.00. Following the purchase, the insider now owns 35 shares in the company, valued at approximately $907.55. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 88,200 shares of company stock worth $2,373,446. Corporate insiders own 44.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Crestline Management LP Acquires 8,442 Shares of Reata Pharmaceuticals Inc (RETA)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://ledgergazette.com/2018/03/21/crestline-management-lp-has-1-95-million-position-in-reata-pharmaceuticals-inc-reta.html.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.